Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Factors Influencing Engagement and Utilisation of Opium Tincture-Assisted Treatment for Opioid Use Disorder: A Qualitative Study in Tehran, Iran Publisher Pubmed



Noroozi A1 ; Conigrave KM2, 3 ; Mirrahimi B4 ; Bastani P5 ; Charkhgard N1, 6 ; Salehi M1, 6 ; Narenjiha H7 ; Vaziri A1 ; Kebriaeezadeh A4, 8
Authors
Show Affiliations
Authors Affiliations
  1. 1. Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Addiction Medicine, Sydney School of Medicine (Central Clinical School), The University of Sydney, Sydney, Australia
  3. 3. Drug Health Services, Royal Prince Alfred Hospital, Sydney, Australia
  4. 4. Department of Pharmacoeconomics and Pharmaceutical Management, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Anthropology, Brown University, Providence, United States
  6. 6. Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Substance Abuse and Dependence Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
  8. 8. Pharmaceutical Management and Economic Research Center, Tehran University of Medical Sciences, Tehran, Iran

Source: Drug and Alcohol Review Published:2022


Abstract

Introduction: In response to a high burden of opioid use disorder (OUD), Iran established a network of opioid agonist treatment (OAT) centres beginning in 2002. To increase treatment diversity, particularly for patients who use opium as their drug of choice, opium tincture (OT)-assisted treatment was introduced to the network. This study aimed to explore factors influencing OT-assisted treatment selection for OUD in Tehran, Iran. Methods: We conducted 54 in-depth interviews with patients with OUD (n = 33), family members of patients (n = 9) and drug treatment providers (n = 12). Participants were recruited from 12 drug treatment centres across Tehran, between September and November 2019. All interviews were audio-recorded, transcribed and coded in OpenCode 4.02 software and analysed using thematic analysis. Results: Study participants more commonly reported individual-level factors as facilitators (e.g. to reduce harms associated with illicit opioid use, achieve recovery through a gradual dose reduction regimen combined with Congress 60 recovery program) and structural level factors (e.g. low adoption by OAT system and lack of familiarity of treatment providers) as barriers for utilisation of OT-assisted treatment regimens. OT was perceived to produce lower levels of physiological dependence than methadone, but the requirement for twice supervised dosing was restrictive. Low familial and community acceptance were also seen as barriers to access. Discussion and Conclusions: This research identified a range of perceived benefits for OT-assisted treatment ranging from harm reduction to an intermediate step to achieve recovery. However, several structural-, individual-, familial- and community-level barriers impede its availability and acceptability. © 2021 Australasian Professional Society on Alcohol and other Drugs.
Other Related Docs
31. Opium Use and the Risk of Head and Neck Squamous Cell Carcinoma, International Journal of Cancer (2021)
36. Correlation of Mental Illness and Hiv/Aids Infection, Tehran University Medical Journal (2016)
40. Population Size Estimation of People Who Use Illicit Drugs and Alcohol in Iran (2015-2016), International Journal of Health Policy and Management (2023)
47. Opium Tincture in Iran: Opportunity or Threat?, Iranian Journal of Psychiatry and Behavioral Sciences (2024)